Merger Efficiency and Coordinated Effects: Nothing to Sneeze at? Evidence From Cough and Cold Medicines in the Philippines
Southern Economic Journal · 20.08.2026
DOI: 10.1002/soej.70063 ↗Kurz gefasst
Fachartikel in der Zeitschrift Southern Economic Journal, online erschienen am 20.08.2026. Verfasst von Farasat A. S. Bokhari und 3 weiteren Autor:innen. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
We investigate the competitive effects of a merger in the cough and cold medicines segment between GlaxoSmithKline (GSK) and Pfizer. The parties offered efficiency gains, and authorities concluded the merger would not lessen competition. Using product‐level data from the Philippines, we estimate a structural demand model to assess efficiency and coordination. We find that prices and marginal costs decline for Pfizer, but not for GSK. Further, the price of a close competitor, Sanofi, also increased substantially. The increase in Sanofi prices is likely due to increased coordination, and efficiency gains do not necessarily lead to lower prices.
Zitieren
APA
Bokhari, F. A. S., Ennis, S., Vega, C., & Yan, W. (2026). Merger Efficiency and Coordinated Effects: Nothing to Sneeze at? Evidence From Cough and Cold Medicines in the Philippines. Southern Economic Journal. https://doi.org/10.1002/soej.70063
Vancouver
Bokhari FAS, Ennis S, Vega C, Yan W. Merger Efficiency and Coordinated Effects: Nothing to Sneeze at? Evidence From Cough and Cold Medicines in the Philippines. Southern Economic Journal. 2026. doi:10.1002/soej.70063
BibTeX
@article{Bokhari2026,
author = {Bokhari, Farasat A. S. and Ennis, Sean and Vega, Carlos and Yan, Weijie},
title = {Merger Efficiency and Coordinated Effects: Nothing to Sneeze at? Evidence From Cough and Cold Medicines in the Philippines},
journal = {Southern Economic Journal},
year = {2026},
doi = {10.1002/soej.70063}
}
EUVIMED